Business Wire

Clinical Investigation Shows Herb-Pharma's ViroStop Spray Effective in Reducing Impact of Covid-19

Share

A recent clinical study has shown that the ViroStop anti-viral spray from Swiss company, Herb-Pharma is effective in reducing the impact of Covid-19 for patients with mild to moderate symptoms.

The key benefits were a 60% reduction in viral shedding after using the treatment and a reduction in the severity of clinical respiratory symptoms. The study supports the findings of earlier in-vitro tests where its mix of polyphenols inhibited the growth of the virus in cell cultures.

The study included 170 PCR confirmed SARS-CoV-2 patients at the Complex Medical Clinic in Budapest, Hungary between January 15th, and May 31st, 2021. The volunteers all had mild to moderate respiratory symptoms, having tested positive in PCR tests for Covid-19 at the start of the study, and their symptoms were monitored over 12 days.

Of the 170 volunteers, 86 received a nasopharyngeal spray, the patented ViroStop solution, which contains a mixture of Cistus Creticus and other polyphenol-rich ingredients. Polyphenols when attached to viral protein, mechanically inhibit the workings of the protein, and thus stop the virus from entering the cell. The rest of the 84 patients remained in the control group and were not given the ViroStop solution. Each patient’s symptoms were checked every two days for 12 days.

At the end of the study the level of viral shedding was checked by PCR tests. Those patients who had used the ViroStop spray from the first day after testing positive, showed an almost 60% reduction in viral shedding on day 12, compared to the control group. The study showed that the severity of respiratory clinical symptoms was also reduced in those who used ViroStop spray.

A reduction was also noted in gastrointestinal symptoms compared to the control group. Recent research has shown that a key factor in the spread of the virus is its ability to also multiply in the gastrointestinal tract.

Dr István Jankovics, whose team ran the study commented, “The primary treatment for Covid 19 is, of course, vaccination, however this study means that the use of the ViroStop spray significantly inhibits the amount of SARS CoV-2 in the upper respiratory tract, thus providing an opportunity for the infected person to develop a specific immune response.”

ViroStop is a non-prescription treatment, made from natural ingredients and can be taken safely by children as young as three. Furthermore, at the time of the study, at least three variants of the virus were present in Hungary, so it is reasonable to assume that the solution and the action of polyphenols is effective against all known mutations of Covid-19.

Issued on behalf of:

Herb-Pharma AG
Waldmannstrasse 6,
8001 Zurich, Switzerland

Company email: home@herb-pharma.com
For more information visit: https://www.virostop.info/
Company website: https://www.fytofontana.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media enquiries:
virostop@contextpr.co.uk
+44(0)300 124 6100

Eleanor Smith /  Eleanor.smith@contextpr.co.uk

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Saildrone Closes $60M Financing to Bring Maritime Autonomy to Europe13.5.2025 10:05:00 EEST | Press release

Saildrone, the global leader in maritime autonomy, today announced the closing of a $60 million investment round led by EIFO, the Export and Investment Fund of Denmark. The investment will be used to bring Saildrone technology to Europe to address the urgent need for maritime security for critical infrastructure and wider defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513296505/en/ Four Saildrone Voyager uncrewed surface vehicles (USVs) will be deployed in Danish waters during the summer of 2025 in partnership with the Danish Armed Forces. The operational testing will begin in June and is part of a broader effort to integrate uncrewed systems into Denmark’s defense architecture. The Baltic, North Sea, and European Arctic waters are currently facing unprecedented threats, and the need for persistent maritime domain awareness has never been greater. Saildrone’s extreme endurance unmanned surface vehicl

New Mirakl-Storfund Partnership Offers Businesses Improved Cash Flow on 400+ Marketplaces13.5.2025 10:00:00 EEST | Press release

Storfund has announced a new partnership that will enable businesses to use the fintech’s cash flow solution on the 400+ marketplaces powered by Mirakl, the leading provider of ecommerce software solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513755226/en/ New Mirakl X Storfund partnership launches The solution, called Daily Advance, is the first financing product to be embedded on Mirakl Connect. Designed to eliminate the standard delay of 25 days between sale and payout, Daily Advance will see Storfund pay businesses as soon as they ship their goods, improving their cash flow and supporting their growth. The service will be available on marketplaces globally including Macy’s, Nordstrom, Best Buy, B&Q, Decathlon and Carrefour. The deal comes a few months after Storfund’s launch on TikTok Shop, a partnership which has already seen Storfund finance tens of millions in sales to US sellers. The new partnership wit

Ohana Development Launches ‘Jacob & Co. Beachfront Living by Ohana,’ A Masterpiece of Beachfront Elegance in the UAE13.5.2025 09:00:00 EEST | Press release

Ohana Development, the leading real estate developer renowned for its luxury properties, has launched ‘Jacob & Co. Beachfront Living by Ohana’ in partnership with luxury timepiece and jewellery house Jacob & Co. The project was revealed at Emirates Palace Mandarin Oriental, Abu Dhabi. Located in Al Jurf between Dubai and Abu Dhabi, this USD 1.3 billion development blends natural surroundings with exceptional artistry and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250512533615/en/ Jacob & Co. Beachfront Living by Ohana. (Photo: AETOSWire) Jacob & Co. Beachfront Living by Ohana presents 457 residences comprising of sea-view apartments, villas, penthouses, Sky Mansions, and beachfront mansions—each capturing the spirit of refined coastal living. Penthouses, starting from USD 6 million, feature 180-degree vistas and expansive interiors, while Sky Mansions, starting from USD 21 million, offer 360-degree panoram

TreeFrog Therapeutics Presents Delivery Strategy for Next Generation 3D Cell Therapy Format for Parkinson’s Disease at the 28th Annual ASGCT Meeting in New Orleans13.5.2025 09:00:00 EEST | Press release

TreeFrog Therapeutics, a French biotech specializing in cell therapy is the first company to present a clinical-ready delivery strategy for 3D microtissues cell therapy. The validated approach was demonstrated for their 3D neural microtissues cell therapy treatment for Parkinson’s disease. Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It is a progressive disease characterized by the loss of dopaminergic neurons with a mix of motor symptoms (bradykinesia, rigidity, resting tremor) and non-motor symptoms (cognitive deficits, mood disorders, fatigue). Current treatments provide symptomatic relief only. There is a huge unmet need with a prevalence that has doubled in the last 25 years to an estimated 10 million sufferers, and it is expected to double again by 20501,2. Research into cell replacement strategies for Parkinson’s disease has been ongoing for decades and the promise of cell therapy in the disease has resulted in a dynamic cli

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders13.5.2025 08:00:00 EEST | Press release

Azafaros, a clinical-stage company focused on developing disease-modifying therapeutics to offer new treatment options to patients with rare lysosomal storage disorders, announces the completion of an oversubscribed €132M Series B financing led by Jeito Capital, co-led by Forbion Growth and with additional participation from Seroba, Pictet Group and existing investors Forbion Ventures, Schroders Capital and BioGeneration Ventures (BGV). This financing enables Azafaros to accelerate the development of its lead product nizubaglustat, scheduled to enter Phase 3 studies for Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses later this year, as well as expanding the Azafaros pipeline to other indications. Rachel Mears, Partner at Jeito Capital; Julien Elric, Senior Principal at Jeito Capital; and Audrey Cacaly, Principal at Forbion Growth will also join Azafaros’s Board of Directors as Board members. Founded in 2018 by BGV, leveraging science from Leiden University and Amsterdam U

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye